Full Press Release Details
Biosciences Reports Second Quarter 2025 Financial and Corporate Results
marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling
progress, and continued strengthening of Enveric's differentiated neuroplastogen pipeline and IP platform. Q2 financial results
were consistent with overall performance over the previous four quarters, and development costs were in line with budgeted IND-enabling
Mass., August 14, 2025 - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a
biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today
announced financial results for the second quarter ended June 30, 2025, and provided a comprehensive business update.
second quarter of 2025 represented a period of focused execution across all key areas of our business, most notably with the advancement
of EB-003, our lead drug candidate" said Joseph Tucker, Ph.D., Director and CEO of Enveric. "We disclosed important new data
demonstrating that EB-003 engages both the 5-HT A and 5-HT B receptors through a dual mechanism of
action. We believe this receptor pairing forms the foundation for a novel pharmacological class. With this discovery, we believe EB-003
has emerged as a first-in-class therapeutic candidate with a dual mechanism that represents a unique therapeutic target with real-world
new pharmacological class is defined by agonism at the 5-HT B receptor, which modulates affective tone, impulsivity,
and reward pathways, as well as concurrent partial agonism at the 5-HT A receptor, which supports cortical neuroplasticity.
We believe this novel and unique profile has the potential to promote adaptive rewiring of brain circuits (i.e. neuroplasticity) while
stabilizing emotional reactivity, motivational control, and behavioral regulation (i.e., generally psychological stability). It is expected
to unlock the therapeutic benefits of serotonin mediated plasticity and guide those effects toward outcomes that are durable, broadly
accessible, and clinically relevant for real-world patient populations."
targeting this specific set of neural receptors, the intent is for EB-003 to recalibrate emotional reactivity, facilitate extinction
of maladaptive fear responses, and restore motivational tone. These are mechanisms believed to support lasting recovery in conditions
such as post-traumatic stress disorder (PTSD), treatment resistant depression, and generalized anxiety. The addition of 5-HT B
agonism is intended to guide plasticity into emotionally grounded outcomes; thus, the designation of EB-003 as a first-in-class drug
these advances, EB-003 continues to differentiate itself in a competitive neuropsychiatric drug development landscape, with pre-IND test
data for EB-003 pointing to a fast acting, durable, and non-hallucinogenic treatment for serious mental health conditions where currently
available therapies are either too slow, poorly tolerated, or not very effective."
EB-003, we made meaningful progress in expanding our intellectual property portfolio, which remains a foundational pillar of our strategy.
During the second quarter, we secured an additional patent grant in our EVM-301 portfolio and patent allowances across multiple distinct
chemical classes in our EVM-301 and EVM-401 portfolios, further reinforcing Enveric's leadership in the discovery of rationally
designed neuroplastogens. With a growing portfolio of issued patents and new filings underway, we are seeking to build a durable, competitive
moat around our lead assets and future pipeline candidates."
ahead to the remainder of 2025 and into 2026, we remain sharply focused on filing an Investigational New Drug (IND) application for EB-003
and preparing for its first-in-human study. We also continue to benefit from ongoing dialogue and growing interest from established pharmaceutical
companies with a strategic focus in neuropsychiatry, which underscores the increasing relevance of our platform in a field that has lacked
innovation for far too long."
Quarter and Recent Corporate Highlights
and Preclinical Development
Quarter 2025 Financial Results
loss attributable to common stockholders was $2.5 million for the quarter ending June 30, 2025, or $0.97 per share, compared to a net
loss of $1.9 million, or $3.72 per share, for the same period in 2024. The net loss for the quarter included approximately $0.2 million
in non-cash expenses related to stock-based compensation and other non-cash charges. As of June 30, 2025, Enveric had cash and cash equivalents
of $2.8 million. The Company continues to fund its operations through the use of various financing tools. The Company has raised net
proceeds of $4.9M for the six months ended June 30, 2025.
Biosciences (NASDAQ: ENVB) is a biotechnology company focused on developing next-generation, small-molecule neuroplastogenic therapeutics
that address unmet needs in psychiatric and neurological disorders. By leveraging a differentiated drug discovery platform and a growing
library of protected chemical structures, Enveric is advancing a pipeline of novel compounds designed to promote neuroplasticity without
hallucinogenic effects. Enveric's lead candidate, EB-003, is the first known compound designed to selectively engage both 5-HT A
and 5-HT B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.
more information, please visit www.enveric.com.
press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These
statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking
statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology
such as "plans," "expects" or "does not expect," "proposes," "budgets," "explores,"
"schedules," "seeks," "estimates," "forecasts," "intends," "anticipates"
or "does not anticipate," or "believes," or variations of such words and phrases, or by the use of words or phrases
which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements
may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management
as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated
by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize
and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation
contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or
safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate
or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on
commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors;
hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent
protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a
going concern; and manage its future growth effectively.
discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings
with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.
Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law.
Strategic Advisors, Inc.
Strategic Advisors, Inc.